Kroppsmasseindeks påvirker interferon-beta behandlingsrespons ved multippel sklerose
Hensikten med denne studien var å se om overvekt var en mulig risikofaktor for multippel sklerose (MS). Studien er utført av forskere ved flere helseregioner og ved UiO, og er publisert i det internasjonale tidsskriftet J Neuroimmunol.
Abstract
Obesity is a possible risk factor of multiple sclerosis (MS), but the association between obesity and MS disease activity has not been explored. In a cohort of 86 MS patients, 80% of overweight or obese patients (BMI≥25kg/m(2)) had MRI activity compared to 48% of the normal-weight patients (BMI<25kg/m(2)) (p=0.001) during interferon-beta treatment. NEDA-status (no evidence of disease activity) was defined as a composite that consisted of absence of any relapses, sustained disability-progression and MRI-activity. Among normal-weight patients 26% obtained NEDA-status compared to only 13% of patients with BMI >25 (p=0.05). This may indicate that BMI affects interferon-beta treatment response.
Reference: